No Evidence of Disease Clinical Trial
Official title:
Clinical Protocol for an Open Label Study of Celecoxib (SC-58635) on the Acute Effect of Human UV-Irradiation
This clinical trial studies celecoxib in decreasing the damaging effects of sunburn in healthy volunteers. Celecoxib may reduce skin damage by blocking enzymes associated with sunburn in healthy volunteers.
Status | Completed |
Enrollment | 25 |
Est. completion date | December 2004 |
Est. primary completion date | December 2004 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - The subject has Fitzpatrick skin type I, II, or III - If the subject is female and of childbearing potential (women are considered not of childbearing potential if they are at least 2 years post-menopausal and/or surgically sterile): - Has been using adequate contraception (e.g., condom, intrauterine device [IUD], diaphragm and spermicide gel combination) since her last menses and will use adequate contraception during the study, and - Is not lactating, and - Will begin taking study drug beginning 2 days after onset of menses - The subject is willing to abstain from the use of other non-steroidal anti-inflammatory drugs (NSAIDs) for the duration of the study - The subject is willing to abstain from the use of all topical agents applied to the buttocks for the duration of the study with the exception of lotion - The subject is willing to participate for the duration of the study - The subject has provided written informed consent prior to administration of any study related procedures Exclusion Criteria: - The subject is currently taking any medication that may alter the sunlight response or cause an adverse reaction - The subject has a history of melanoma, lupus, psoriasis, rosacea, porphyria, photosensitivity disorder, connective tissue disorder, or any disease that would increase the risk associated with study participation - The study has excessive hair, blemishes, nevi, uneven pigmentation, sunburn or suntan on the buttocks - The subject has sun bathed or used a tanning bed to expose the buttocks within 12 months of admission to the study - The subject has inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis), a chronic or acute renal or hepatic disorder or a significant coagulation defect or any other condition which in the Investigator's opinion might preclude use of an NSAID (e.g., congestive heart failure) - The subject has an active malignancy of any type; subjects who have a history of nonmelanoma skin cancer and have been treated are acceptable; subjects with a history of other malignancies that have been surgically removed and who have no evidence of recurrence for at least five years prior to study enrollment are also acceptable - The subject has active or suspected peptic ulceration or gastrointestinal bleeding - The subject has received any investigational medication within 30 days prior to the first dose of study medication or is scheduled to receive an investigational drug other than celecoxib during the course of this study - The subject has a known hypersensitivity to cyclooxygenase-2 inhibitors, sulfonamides, or NSAIDs - The subject has significant medical or psychosocial problems that would make the subject a poor candidate, in the opinion of the principal investigator - The subject is currently taking celecoxib |
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
United States | University of Rochester | Rochester | New York |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes in the erythema response in human subjects exposed to a range of erythemic doses of solar-simulated ultraviolet light before and after celecoxib treatment | Baseline up to day 11 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT01230346 -
Culturally-Informed Counseling in Latinas at High Risk for Hereditary Breast or Ovarian Cancer
|
N/A | |
Recruiting |
NCT03156309 -
Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission
|
Phase 1 | |
Active, not recruiting |
NCT02780401 -
Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission
|
Phase 1 | |
Completed |
NCT02099136 -
Celecoxib in Preventing the Damaging Effects of Sunburn in Healthy Volunteers
|
Phase 2 | |
Completed |
NCT03725449 -
Internet-based Intervention for Skin Self-Examination in Participants With Increased Risk for Melanoma
|
N/A | |
Completed |
NCT01497431 -
Se-Methyl-Seleno-L-Cysteine or Selenomethionine in Preventing Prostate Cancer in Healthy Participants
|
Phase 1 | |
Withdrawn |
NCT03120390 -
Physical Activity in Reducing Metabolic Dysregulation (MetD) in Obese Latina Breast Cancer Survivors
|
N/A | |
Terminated |
NCT02735512 -
MDSC Clinical Assay in Finding and Monitoring Cancer Cells in Blood and Urine Samples From Patients With or Without Localized or Metastatic Bladder Cancer
|
||
Completed |
NCT01149096 -
Collection of Bone Marrow From Donors Treated With or Without Filgrastim
|
Phase 3 | |
Completed |
NCT02961790 -
Oxybutynin Chloride in Managing Hot Flashes
|
Phase 3 | |
Completed |
NCT02288416 -
Video-Based Intervention in Reducing Anxiety in Patients Undergoing Lung Cancer Screening
|
N/A | |
Completed |
NCT01698294 -
Biomarkers in Post-Menopausal Women Receiving Flaxseed
|
N/A | |
Completed |
NCT00896974 -
Study of 9cUAB30 in Healthy Participants
|
Phase 1 | |
Terminated |
NCT03284346 -
Exercise in Targeting Metabolic Dysregulation in Stage I-III Breast or Prostate Cancer Survivors
|
N/A |